Influenza is a significant burden for patients and health care professionals
Do you see at-risk patients?
These populations can be at risk for complications from influenza2,a:
Adults 65 years
weakened immune system
aThe populations noted here are found in the general public and recognized by the CDC. Rapivab is indicated for adults aged 18+.
No substantive data exist on the use of Rapivab in adults with concurrent illness or with weakened immune system.
Many conditions can increase the risk of serious complications4
The CDC has identified these concomitant conditions that may put patients at greater risk of complications from influenza.
Chronic lung disease
(e.g., chronic obstructive pulmonary disease (COPD), cystic fibrosis)
(e.g., congenital heart disease, congestive heart failure, coronary heart disease)
(e.g., diabetes mellitus)
(e.g., inherited metabolic disorders, mitochondrial disorders)
(e.g., chronic kidney disease, moderate to severe renal disease)5
(e.g., hepatitis, chronic liver disease, cirrhosis)5
Neurological and neurodevelopmental conditions
(e.g., cerebral palsy, epilepsy, stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)
(with a body mass index of 40 or higher)
(e.g., sickle cell disease)